+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the optimal doses of the drug E2086 compared to placebo in adults with narcolepsy, a condition characterized by excessive daytime sleepiness EDS. The study focuses on reducing EDS as measured by the Mean Sleep Latency MSL using the first four maintenance of wakefulness tests MWTs. This Phase 2 trial includes participants diagnosed with either narcolepsy type 1 NT1 or type 2 NT2 within the last 10 years. Participants will be randomly assigned to receive either E2086 or a matching placebo tablet taken orally once daily for four weeks at low, middle, and high doses. Each dosing period is separated by a washout period of at least seven days, with a total treatment duration of approximately 14 weeks. This design allows comparison of the effects of different doses of E2086 on narcolepsy symptoms. During the study, participants will undergo assessments to measure changes in sleep latency, cataplexy episodes, and sleepiness scales. Additional safety evaluations include monitoring for adverse events, laboratory tests, vital signs, ECG parameters, and suicidality assessments. Blood samples will be collected to analyze drug concentration levels. The study involves regular monitoring up to Day 113 and aims to assess both efficacy and safety over the course of treatment and follow-up.

Age: 18Years +All GendersPhase 2
57 locations
E

Actively Recruiting

This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.

Age: 18Years +All GendersPhase 3
218 locations
O

Actively Recruiting

Researchers are evaluating AZD9574, both alone and combined with other anti-cancer drugs, in people with advanced solid tumors that have returned or worsened. This modular phase IIIa study aims to assess the safety, tolerability, how the drug moves and acts in the body, and preliminary effectiveness. The study includes participants with various advanced cancers, including ovarian, breast, pancreatic, prostate, and glioma, among others, with specific genetic mutations related to DNA repair. Participants will receive AZD9574 alone or with other treatments like temozolomide, trastuzumab deruxtecan, or datopotamab deruxtecan, depending on their cancer type and study module. The study has several parts, including dose escalation and expansion phases, with some participants receiving oral AZD9574 and others receiving combinations with intravenous drugs. Some modules include additional imaging studies and biomarker testing to evaluate drug effects. During the study, participants will undergo regular assessments including scans, blood tests, heart monitoring, and evaluations of cancer response and side effects. Researchers will track adverse events, lab changes, and performance status from first dose through about three years post-treatment. The study also monitors how the drug is processed in the body and its effects on tumors over time. Participation length varies depending on study module and response, with ongoing safety follow-up after treatment ends.

Age: 18Years - 130YearsAll GendersPhase 1Phase 2
32 locations